免疫检查点抑制剂在卵巢癌中的治疗进展与挑战

Progress and Challenges of Immune Checkpoint Inhibitors in the Treat-ment of Ovarian Cancer

卵巢癌死亡率居妇科恶性肿瘤首位,亟待寻找新的治疗方法或策略改善卵巢癌不良预后。随着免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现,目前已有多种ICIs被批准用于各种肿瘤治疗,但在卵巢癌中,无论是单药ICIs还是联合治疗方案,多数患者仍不能从中获益。不过部分卵巢癌亚组患者是ICIs的潜在获益人群,因此卵巢癌免疫治疗仍是值得关注的研究方向。本文对目前ICIs以及联合不同药物在卵巢癌的临床研究进展、预测疗效的生物标记物以及耐药性等相关问题进行综述,旨在更好地理解卵巢癌免疫治疗的现状,为优化卵巢癌的药物治疗提供新的思路。

The mortality rate of ovarian cancer ranks the first among gynecological malignancies,and it is urgent to find new therapeutic methods or strategies to improve the poor prognosis of ovarian cancer.With the emergence of immune check-point inhibitors(ICIs),a variety of them have been approved for the treatment of various tumors.Most patients,however,do not benefit from either single ICIs or combination therapy in the treatment of ovarian cancer.Notably,some subgroups of ovari-an cancer patients are the potential beneficiaries of ICIs,so ovarian cancer immunotherapy is still a research direction worthy of attention.This article reviews the current clinical research progress of ICIs and the combination of different drugs for ovarian cancer,biomarkers that predict efficacy,and ICIs re-sistance.The goal is to enhance the understanding of the cur-rent landscape of immune therapy for ovarian cancer,and offer new insights for the clinical treatment of the disease.